Frontera Therapeutics Files for Hong Kong IPO as the First AAV Gene Therapy Company, Valued at $527 Million

Dec 24, 2025 11:01 CST Updated 11:01

Frontera Therapeutics

Innovative Gene Therapy Drug R&D and Producer

On December 23, gene therapy companyFangFrontera Therapeutics Submits A1 Filing for Hong Kong IPO, Becoming the First AAV Gene Therapy Company to Apply for Listing in Hong Kong; UBS and CMB International Act as Joint Sponsors.

The company was registered in 2019, completed a $35 million Series A financing in 2021, and a $163 million Series B financing in 2022, with cumulative financing reaching $198 million. The post-Series B valuation in 2022 was $527 million. Major shareholders include OrbiMed.Capital, Hongyuan Capital, Boyu Capital, Sequoia China, ZhenXinGu etc.

Frontera Therapeutics' engineered adeno-associated virus (AAV) capsids, along with optimized payload designs supported by advanced manufacturing processes, effectively reduce the immunogenicity of recombinant adeno-associated virus (rAAV), offering safer and longer-lasting therapeutic outcomes.Frontera TherapeuticsFrontera Therapeutics is one of the few companies globally and the first in China to establish a commercial-scale Baculovirus/Sf9 insect cell (Bac/Sf9) system for the production of rAAV gene therapy drugs, providing a highly competitive cost advantage for future product commercialization.

Core PipeThe pipeline includes rAAV gene therapy FT-002 for XLRP, rAAV gene therapy FT-003 for nAMD and DME, and rAAV gene therapy FT-001 for RPE65-mediated IRD.

Follow the official account below to explore the world with you!